相似文献
1
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient.
Cancer Cell. 2021 Aug 9;39(8):1037-1038. doi: 10.1016/j.ccell.2021.06.015. Epub 2021 Jun 26.
2
Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Front Immunol. 2021 Jun 30;12:690698. doi: 10.3389/fimmu.2021.690698. eCollection 2021.
3
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
4
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
5
[The value of booster vaccination against COVID-19].
Ned Tijdschr Geneeskd. 2021 Dec 23;165:D6623.
6
Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.
J Infect Dev Ctries. 2021 May 31;15(5):653-656. doi: 10.3855/jidc.15368.
7
Behavioral and social science in support of SARS-CoV-2 vaccination: National Institutes of Health initiatives.
Transl Behav Med. 2021 Jul 29;11(7):1354-1358. doi: 10.1093/tbm/ibab067.
8
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
Proc Natl Acad Sci U S A. 2021 Jul 13;118(28). doi: 10.1073/pnas.2026207118.
9
Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists.
Int J Rheum Dis. 2021 Jun;24(6):746-757. doi: 10.1111/1756-185X.14107. Epub 2021 May 10.
10
A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
Emerg Microbes Infect. 2021 Dec;10(1):1555-1573. doi: 10.1080/22221751.2021.1957400.
引用本文的文献
1
Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.
Ann Hematol. 2024 Dec;103(12):4971-4980. doi: 10.1007/s00277-024-05869-8. Epub 2024 Jul 15.
2
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine.
Front Oncol. 2023 Feb 14;13:1117815. doi: 10.3389/fonc.2023.1117815. eCollection 2023.
3
Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review.
Chonnam Med J. 2023 Jan;59(1):24-30. doi: 10.4068/cmj.2023.59.1.24. Epub 2023 Jan 25.
4
Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine.
Vaccines (Basel). 2022 Sep 26;10(10):1613. doi: 10.3390/vaccines10101613.
5
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Int Immunopharmacol. 2022 Sep;110:109046. doi: 10.1016/j.intimp.2022.109046. Epub 2022 Jul 12.
6
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.
Nat Cancer. 2021 Dec;2:1321-1337. doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27.
7
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.
Cancer Discov. 2022 Feb;12(2):303-330. doi: 10.1158/2159-8290.CD-21-1368. Epub 2021 Dec 10.
8
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis.
Blood Adv. 2022 Apr 12;6(7):2014-2034. doi: 10.1182/bloodadvances.2021006333.
9
Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
Am J Hematol. 2022 Feb 1;97(2):E67-E69. doi: 10.1002/ajh.26418. Epub 2021 Nov 30.
10
Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review.
Front Oncol. 2021 Nov 4;11:759108. doi: 10.3389/fonc.2021.759108. eCollection 2021.
本文引用的文献
1
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
Lancet Respir Med. 2021 Nov;9(11):1255-1265. doi: 10.1016/S2213-2600(21)00357-X. Epub 2021 Aug 13.
2
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2. doi: 10.1016/j.ccell.2021.06.009. Epub 2021 Jun 18.
3
Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity.
J Clin Microbiol. 2021 Aug 18;59(9):e0098921. doi: 10.1128/JCM.00989-21.
4
Seroconversion rates following COVID-19 vaccination among patients with cancer.
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.
5
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
Ann Intern Med. 2021 Sep;174(9):1330-1332. doi: 10.7326/L21-0282. Epub 2021 Jun 15.
6
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
7
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Blood. 2021 Jan 14;137(2):185-189. doi: 10.1182/blood.2020008758.
8
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965.
9
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.
Viruses. 2020 May 6;12(5):513. doi: 10.3390/v12050513.
10
Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine.
J Infect Dis. 2008 Aug 1;198(3):299-304. doi: 10.1086/589722.
Zotero 插件